Active — Not RecruitingNot Applicable

Role of Metformin in Posterior Capsule Opacification

Austria40 participantsStarted 2022-10-12

Plain-language summary

Determination of concentrations of systemically applied metformin in human lens capsule and its ability to lower the proliferation rate of human lens epithelial cells in vitro.

Who can participate

Age range21 Years – 105 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age-related cataract * Diabetes mellitus type II * Metformin treatment * Age 21 or older * Written informed consent prior to surgery Exclusion Criteria: * Diabetes mellitus type I * Previous ocular surgery or trauma regarding cataract surgery * Previous vitrectomy * Pregnancy (pregnancy test will be taken in women of reproductive age)

What they're measuring

Metformin concentration in the human lens capsule

Timeframe: 12 months

Trial details

NCT IDNCT07176338

SponsorVienna Institute for Research in Ocular Surgery

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-10-01

View on ClinicalTrials.gov More Cataract trials